Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

Purpose: Microarray technology was used to identify gene expression markers that predict response to the orally available farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in acute myelogenous leukemia (AML). Experimental Design: Gene expression profiles from 58 bone marrow samples from a cohort of relapsed and refractory AML patients were analyzed on the Affymetrix U133A gene chip that contains ∼22,000 genes. Results: Supervised statistical analysis identified eight gene expression markers that could predict patient response to tipifarnib. The most robust gene was the lymphoid blast crisis oncogene (AKAP13), which predicted response with an overall accuracy of 63%. This gene provided a negative predictive value of 93% and a positive predictive value of 31% (increased from 18%). AKAP13 was overexpressed in patients who were resistant to tipifarnib. When overexpressed in the HL60 and THP1 cell lines, AKAP13 increased the resistance to tipifarnib by approximately 5- to 7-fold. Conclusion: Diagnostic gene expression signatures may be used to select a group of AML patients that might respond to tipifarnib.

[1]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Yusuke Nakamura,et al.  Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. , 2002, Molecular cancer therapeutics.

[3]  M. Lewis,et al.  Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.

[4]  R. Kurzrock,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and , 2022 .

[5]  David Elashoff,et al.  Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study , 2002, The Lancet.

[6]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[7]  Takeshi Urano,et al.  Activation of the Lbc Rho Exchange Factor Proto-Oncogene by Truncation of an Extended C Terminus That Regulates Transformation and Targeting , 1999, Molecular and Cellular Biology.

[8]  G. Prendergast,et al.  Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. , 2002, Cancer research.

[9]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[10]  W. Scheithauer,et al.  Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[12]  C. Peschle,et al.  Interleukin-3 receptor in acute leukemia , 2004, Leukemia.

[13]  Channing J Der,et al.  Farnesyltransferase inhibitors: promises and realities. , 2002, Current opinion in pharmacology.

[14]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[15]  I. Fraser,et al.  Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. , 1991, The Journal of biological chemistry.

[16]  David A. Williams,et al.  Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction products. , 1994, Oncogene.

[17]  D. Coppola,et al.  The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[18]  R. Muschel,et al.  Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. , 2003, Cancer research.

[19]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[20]  F. Khuri,et al.  Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-κB Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-κB-regulated Gene Expression and Up-regulation of Apoptosis* , 2004, Journal of Biological Chemistry.

[21]  R. Foisner,et al.  Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Morgan,et al.  Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. , 2001, Blood.

[23]  R. Coombes,et al.  Estrogen receptors and proliferation markers in primary and recurrent breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[25]  B. Lim,et al.  The Hematopoiesis-Specific GTP-Binding Protein RhoH Is GTPase Deficient and Modulates Activities of Other Rho GTPases by an Inhibitory Function , 2002, Molecular and Cellular Biology.

[26]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[27]  M. Polymeropoulos,et al.  Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib , 2004, Clinical Cancer Research.

[28]  M. Dowsett,et al.  Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Sebti,et al.  Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ , 2000, Oncogene.

[30]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[31]  E. Estey,et al.  Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Ha,et al.  Inhibition of Farnesyltransferase Prevents Collagen-Induced Arthritis by Down-Regulation of Inflammatory Gene Expression through Suppression of p21ras-Dependent NF-κB Activation1 , 2004, The Journal of Immunology.

[33]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[34]  J. Karp,et al.  Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. , 2003, Blood.

[35]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[36]  M. Olson,et al.  Direct Involvement of the Small GTP-binding Protein Rho in lbc Oncogene Function (*) , 1995, The Journal of Biological Chemistry.

[37]  M. Morgan,et al.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? , 2000, Blood.

[38]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[39]  G. Ahmann,et al.  Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma , 2003, Blood.

[40]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.